Herpes simplex virus antiviral drug resistance - current trends and future prospects
Herpes simplex virus antiviral drug resistance - current trends and future prospects
复制标题
DOI：
10.1016/s1386-6532(00)00169-4
复制
发表时间：
2001-06-01
影响因子：
8.8
通讯作者：
Field, HJ
中科院分区：
文献类型：
--
作者：
Field, HJ
单纯疱疹病毒 (HSV) 的各种表现形式已被广泛使用抗病毒药物治疗 40 多年。阿昔洛韦（ACV）是迄今为止最常用的药物。在细胞培养物中进行测试时，大多数 HSV 分离株对 ACV 敏感，ED50 值约为 0.1 mug/ml。 ACV 耐药菌株（定义为 ED50 > 2 mug/ml）在正常患者的临床实践中很少遇到（< 1% 分离株），并且迄今为止没有确凿的证据表明这种发生率正在增加。然而，在治疗期间免疫功能低下的患者中，耐药性 HSV 的发生频率要高得多（约 5% 的分离株），这被认为是导致治疗无效的重要临床问题。这篇综述认为，HSV 正常发病机制中神经元潜伏期的快速建立是耐药性发展发生率低的关键，并导致人们对未来趋势感到乐观。 (C) 2001 Elsevier Science B.V. 保留所有权利。
The various manifestations of herpes simplex virus (HSV) have been widely treated using antiviral agents for more than 40 years. Acyclovir (ACV) is the drug that has been most commonly used to date. When tested in cell culture, the majority of isolates of HSV are sensitive to ACV with ED50 values of approximately 0.1 mug/ml. ACV-resistant strains (defined as having ED50 > 2 mug/ml) are rarely encountered in clinical practice among normal patients (< 1% isolates) and there is no firm evidence, to date, that this incidence is increasing. Resistant HSV occurs much more frequently, however, among immunocompromised patients during treatment (approximately 5% isolates) where this is recognised to be an important clinical problem leading to ineffective therapy. In this review it is argued that the rapid establishment of neuronal latency in the normal pathogenesis of HSV is the key to the low incidence of resistance development and leads to some optimism concerning future trends. (C) 2001 Elsevier Science B.V. All rights reserved.